Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The decision is based on the phase 3 DESTINY-Breast11 trial
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
Subscribe To Our Newsletter & Stay Updated